STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INTENSIFICATION IN ETV6-RUNX1-POSITIVE PATIENTS
EHA Learning Center, Kirsten Bleckmann, 181767
ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY
EHA Learning Center, Simona Soverini, 181772
STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR BIOLOGICALBEHAVIOR OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Yanbo Nie, 181777
IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT
EHA Learning Center, Pietro Merli, 181782
DISCOVERY OF ORALLY BIOAVAILABLE SMALL MOLECULES FOR INHIBITION OF COMPLEMENT C5
EHA Learning Center, Alonso Ricardo, 181787
THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Krisstina gowin, 181792
A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Philippe Moreau, 181747
SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)
EHA Learning Center, Peter Hillmen, 181752
L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY
EHA Learning Center, Kami Maddocks, 181757
PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Naval Daver, 181761
DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL AFTER CD19 CAR (19-28Z) T CELL THERAPY
EHA Learning Center, Eric Smith, 181766
COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY
EHA Learning Center, Ilaria Stefania Pagani, 181771
IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Montalban-Bravo, 181776
INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED RISK FACTORS
EHA Learning Center, M. Heuser, 181781
CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC CELLS USING CRISPR-CAS9
EHA Learning Center, Cédric Cleyrat, 181786
FRONT-LINE VASCULAR ACCESS DEVICES IN ACUTE LEUKEMIAS - PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) VERSUS TRADITIONAL CENTRAL VENOUS CATHETER (CVC): A PHASE IV RANDOMIZED TRIAL (NCT02405728)
EHA Learning Center, Claudio Cerchione, 181791
EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
EHA Learning Center, Katja C Weisel, 181746
BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
EHA Learning Center, Paula Cramer, 181751
SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY
EHA Learning Center, Marie Maerevoet, 181756
UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ≥65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY
EHA Learning Center, Andrew Wei, 181760
BLINATUMOMAB VS SOC CHEMOTHERAPY IN FIRST SALVAGE COMPARED WITH SECOND OR GREATER SALVAGE IN A PHASE 3 STUDY
EHA Learning Center, Herve Dombret, 181765
MYC-DEPENDENT REPRESSION MECHANISM OF THE MIR-150 TRANSCRIPTIONAL REGULATION IN CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, Nikola Curik, 181770
ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS
EHA Learning Center, Shyamala Navada, 181775
OUTCOMES OF NON T CELL-DEPLETED HAPLOIDENTICAL HSCT VERSUS HSCT FROM MATCHED SIBLING DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION, AN ALWP-EBMT STUDY
EHA Learning Center, Dalila Salvatore, 181780
EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
EHA Learning Center, Britta Höchsmann, 181785
EFFECTIVE KEY WORKERS REDUCE THE NEED FOR CANCER SUPPORT GROUPS: RESULTS OF A POPULATION BASED SURVEY FROM GREATER MANCHESTER CANCER PATHWAY BOARD (GMCPB).
EHA Learning Center, Jo Tomlins, 181790
OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL
EHA Learning Center, Meletios A Dimopoulos, 181745
IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
EHA Learning Center, Nitin JAIN, 181750
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
EHA Learning Center, Matthew Matasar, 181755
CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Karen Thudium Mueller, 181764
FC GAMMA RECEPTOR 2B IS CRITICAL FOR BCR-ABL MEDIATED LEUKEMOGENESIS
EHA Learning Center, Oliver Herrmann, 181769
AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)
EHA Learning Center, Guillermo Montalban-Bravo, 181774
IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY
EHA Learning Center, Iskra Pusic, 181779
SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM ANALYSIS OF THE SCNIR EUROPE
EHA Learning Center, Cornelia Zeidler, 181784
HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA
EHA Learning Center, Andrew Davies, 181789
A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Joseph Mikhael, 181744
IS FCR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS?
EHA Learning Center, carolina Cuellar, 181749
CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): PHASE IB STUDY IN RELAPSED OR REFRACTORY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR MARGINAL ZONE LYMPHOMA
EHA Learning Center, R Bouabdallah, 181754
SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (≥65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Keith Pratz, 181759
GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
EHA Learning Center, Stephan A. Grupp, 181763
A SECOND GENERATION LYSOSOMOTROPIC AGENT DRIVES LEUKAEMIC STEM CELL DIFFERENTIATION AND SENSITIZES THEM TO TYROSINE KINASE INHIBITOR TREATMENT IN VITRO AND IN VIVO
EHA Learning Center, Pablo Baquero, 181768
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS.
EHA Learning Center, Jakob Werner Hansen, 181773
SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Taehyung Kim, 181778
HEREDITARY HEMATOLOGIC MALIGNANCIES: GENETIC COUNSELING IMPLEMENTATION IN A LARGE LEUKEMIA CENTER
EHA Learning Center, Courtney DiNardo, 181783
QUALITY OF LIFE WITH MELPHALAN/PREDNISONE PLUS EITHER THALIDOMIDE (MPT-T) OR LENALIDOMIDE (MPR-R) IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE HOVON87/NMSG18 STUDY
EHA Learning Center, Claudia Stege, 181788
PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Meletios A Dimopoulos, 181743
CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC
EHA Learning Center, Panagiotis Baliakas, 181748
CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
EHA Learning Center, Yi Lin, 181753
ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
EHA Learning Center, Eytan M. Stein, 181758
NLPHL - A Forgotten Entity?
EHA Learning Center, Andreas Engert, 184498
Non substitutive therapies for haemophilia
EHA Learning Center, Michael Makris, 184501
Early Phase Clinical Trials In Children: The European Perspective
EHA Learning Center, C.M. Zwaan, 184504
How to present and how to get published: Personal perspective from the Blood Editor-in-chief
EHA Learning Center, Bob Löwenberg, 184507
Double Hit Lymphoma
EHA Learning Center, Martine Chamuleau, 184497
Factor VIII based
EHA Learning Center, Flora Peyvandi, 184500
New drugs for children with hematological malignancies - The US perspective
EHA Learning Center, Peter Adamson, 184503
Introduction: Early Career Committee, Overview on Early Career Session 2 and the two Bite-size classes
EHA Learning Center, Verena I Gaidzik, 184506
AML after 3+7
EHA Learning Center, Norbert Vey, 192903
Prognostic factors in CLL: When, which and how?
EHA Learning Center, Michael Doubek, 192905
Heterogeneity in the making of blood
EHA Learning Center, David Scadden, 184495
Microparticles and Bloodtransfusion
EHA Learning Center, Thierry Burnouf, 192904
Jean Bernard Lifetime Achievement Award: Introduction
EHA Learning Center, Tony Green, 184492
CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Francesca Gay, 181697
HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS
EHA Learning Center, Monique C. Minnema, 181698
A REVISED STAGING SYSTEM FOR WALDENSTRÖM'S MACROGLOBULINEMIA
EHA Learning Center, Efstathios Kastritis, 181702
SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) TREATED WITH RITUXIMAB (R) MONOTHERAPY: A LONG TERM FOLLOW-UP STUDY ON 104 PATIENTS
EHA Learning Center, Cristina Kalpadaki, 181703
JAK2 V617F HAEMATOPOIETIC CLONES WITH DIFFERENT EXPANSION KINETICS ARE DETECTABLE SEVERAL YEARS PRIOR TO MPN DIAGNOSIS
EHA Learning Center, Thomas McKerrell, 181707
DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM
EHA Learning Center, Ruggiero Norfo, 181708
BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL
EHA Learning Center, Tim H. Brümmendorf, 181712
CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS
EHA Learning Center, Markus Pfirrmann, 181713
PIWIL4 ACTS AS A PIRNA BINDING, EPIGENETICALLY ACTIVE AND GROWTH REGULATORY PROTEIN IN HUMAN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Shiva Bamezai, 181716
METTL3 CONTROLS TRANSLATION OF TARGET MRNAS BY N6 METHYLATION OF ADENOSINE RESIDUES IN THEIR CODING SEQUENCE AND CONSTITUTES A NOVEL THERAPEUTIC VULNERABILITY OF ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Konstantinos Tzelepis, 181717
POSITION OF THE GFI1B ZINC FINGER MUTATION DECOUPLES CD34 EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GFI1B-RELATED PLATELET DISORDERS
EHA Learning Center, William STEVENSON, 181721
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
EHA Learning Center, James Bussel, 181722
THE T-CELL LEUKEMIA ASSOCIATED RIBOSOMAL RPL10 R98S MUTATION ENHANCES JAK-STAT SIGNALING
EHA Learning Center, S Vereecke, 181726
NFATC3-PLA2G15 IS A NOVEL INTERGENICALLY SPLICED CHIMERA THAT IS ASSOCIATED WITH AGGRESSIVE T-ACUTE LYMPHOBLASTIC LEUKAEMIA BIOLOGY.
EHA Learning Center, Jonathan Bond, 181727
IMPACT OF A NEW ELECTRONIC ALERT SYSTEM (V2.0) FOR VENOUS THROMBOEMBOLISM PREVENTION IN HOSPITALISED CANCER PATIENTS.
EHA Learning Center, Rocío Figueroa, 181731
IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1 GENE DEFECT CAUSING ANTITHROMBIN DEFICIENCY HARDLY DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF EXON 6.
EHA Learning Center, María Eugenia De La Morena-Barrio, 181732
ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVIRONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Yuan Kong, 181736
HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Rima Saliba, 181737
CRIZANLIZUMAB, A P-SELECTIN INHIBITOR, INCREASES THE LIKELIHOOD OF NOT EXPERIENCING A SICKLE CELL-RELATED PAIN CRISIS WHILE ON TREATMENT: RESULTS FROM THE PHASE II SUSTAIN STUDY
EHA Learning Center, Abdullah Kutlar, 181741
FREE IRON IN SERA OF PATIENTS WITH SICKLE CELL DISEASE CONTRIBUTES TO THE RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS
EHA Learning Center, Kristof Van Avondt, 181742
DEPTH OF RESPONSE AS SURROGATE MARKER FOR PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH VMP AND RD: GEM2010MAS65
EHA Learning Center, María-Victoria Mateos, 181696
DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP
EHA Learning Center, Paul J Bröckelmann, 181701
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
EHA Learning Center, Veronica Caraffini, 181706
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
EHA Learning Center, R Hehlmann, 181711
A MONOALLELIC LOSS-OF-FUNCTION MUTATION IN THE THROMBOPOIETIN (THPO) GENE IS RESPONSIBLE FOR A NEW FORM OF INHERITED THROMBOCYTOPENIA (IT)
EHA Learning Center, Patrizia Noris, 181720
THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALL
EHA Learning Center, Tim Pieters, 181725
COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTS
EHA Learning Center, Darko Antic, 181730
MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS
EHA Learning Center, Vera van Hoeven, 181735
HEREDITARY XEROCYTOSIS: CLINICAL AND BIOLOGICAL PRESENTATION AT DIAGNOSIS IN A RETROSPECTIVE SERIES OF 103 PATIENTS
EHA Learning Center, loic garcon, 181740
DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT
EHA Learning Center, Shaji K Kumar, 181695
EARLY CHEMOTHERAPY INTENSIFICATION WITH ESCALATED BEACOPP IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A POSITIVE INTERIM PET-CT AFTER 2 ABVD CYCLES: LONG-TERM RESULTS OF THE GITIL/FIL HD 0607 TRIAL
EHA Learning Center, Andrea Gallamini, 181700
EFFECTIVENESS OF LSD1 INHIBITION FOR THE TREATMENT OF MPN
EHA Learning Center, Jonas Jutzi, 181705
INITIAL REDUCTION OF THERAPY BEFORE COMPLETE WITHDRAWAL IMPROVES THE CHANCE OF SUCCESSFUL TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKAEMIA (CML): YEAR 2 RESULTS IN THE BRITISH DESTINY STUDY
EHA Learning Center, Richard Clark, 181710
NUCLEOSOME BINDING PROTEIN HMGN1 BLOCKS MYELOID DIFFERENTIATION AND PROMOTES CLONAL DOMINANCE VIA ABERRANT HISTONE ACETYLATION
EHA Learning Center, Lucia Cabal-Hierro, 181715
NOVEL PERSPECTIVES IN GENOTYPE-PHENOTYPE CORRELATIONS IN MYH9-RELATED DISEASE: NO LONGER JUST A MATTER OF HEAD OR TAIL
EHA Learning Center, Carlo Zaninetti, 181719
TNF RECEPTOR 2 IS REQUIRED FOR RIP1-DEPENDENT CELL DEATH IN LEUKEMIA
EHA Learning Center, Júlia Aguadé-Gorgorió, 181724
CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES
EHA Learning Center, Peter Balen, 181734
STEM CELL TRANSPLANTATION IN PYRUVATE KINASE DEFICIENCY
EHA Learning Center, Stephanie van Straaten, 181739